TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19171070
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention for problem focused therapy (2 x 2 hours)
Study: 24576321
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (100 mW) - best dose from phase 1
Study: 25832687
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with GCP
Study: 20886654
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment of rest for 5 min
Study: 19034470
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis before skin incision (Group A)
Study: 29943364
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy
Study: 3898689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metyrapone and aminoglutethimide
Study: 8067556
Drug: Topical EMLA
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EMLA cream applied to the skin of the flank overlying the kidney 90 min prior to the ESWL procedure.
Study: 25683285
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/day
Study: 16945169
Drug: High-dose levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose levamisole combined with 5-FU and leucovorin
Study: 14529939
Drug: Melphalan 100
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 100 mg/m2 (three to four doses at 8- to 12-week intervals)
Study: 7734897
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment
Study: 9428465
Drug: Dilution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilution of predialysis sample with heparin or saline
Study: 31465156
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi therapy (Sun style Tai Chi exercise, 5 min warm-up, 45 min main exercise, 10 min meditation, conducted twice a week for 40 sessions over 5 months)
Study: 20731878
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin 0.5%
Study: 20731878
Drug: Cream (control)
Normalized name: Oral Cream
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (control)
Study: 16878680
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri formulation LR-2 (2 x 10(8) CFU per day)
Study: 12874466
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (0.9 g thrice daily)
Study: 7813605
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid application of 6 mg benperidol (BPD)
Study: 7813605
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet application of 6 mg benperidol (BPD)
Study: 12972855
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (interpretive and supportive)
Study: 8568142
Drug: Patch tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch tests
Study: 20493430
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg
Study: 1425897
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of indomethacin
Study: 11605920
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (10 microg/kg estimated fetal weight x 1.25 placental correction) given once at intrahepatic vein transfusion
Study: 10803490
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment strategy (diuretics or beta-adrenergic blockers)
Study: 12749757
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg/day
Study: 25616607
Drug: Active azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active azithromycin (1 g) + placebo doxycycline
Study: 25616607
Drug: Active doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active doxycycline (100 mg twice a day ×7 days) + placebo azithromycin
Study: 25616607
Drug: Reverse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse therapy (active doxycycline if first treated with active azithromycin)
Study: 25616607
Drug: Reverse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse therapy (active azithromycin if first treated with active doxycycline)
Study: 8496526
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications (overall)
Study: 2967183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisoprolol (B)
Study: 31245006
Drug: Low-dose behavioral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose behavioral treatment (8 sessions)
Study: 8455424
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 million units, three times weekly)
Study: 8455424
Drug: Prednisolone withdrawal
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone withdrawal followed by interferon alfa (3 million units, three times weekly)
Study: 8455424
Drug: Spontaneous normalization
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous normalization without treatment
Study: 8147337
Drug: Counseling to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling to increase dietary calcium through food consumption to 1500 mg/d (n = 106)
Study: 8817136
Drug: Non buffered
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non buffered crystalloid cardioplegia enriched with glutamate and mannitol (Menasché's solution)
Study: 9489592
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg with cholestyramine 12 g
Study: 26385341
Drug: Erythrosine dose
Normalized name: erythrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrosine dose of 220 μM
Study: 30053967
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100 [200]/25 μg
Study: 6135344
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (timolol)
Study: 16047874
Drug: Sodium sulfacetamide
Normalized name: sodium sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium sulfacetamide 10% and sulfur 5% cream with sunscreens
Study: 7516297
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine
Study: 10571797
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg q.d.
Study: 10571797
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg plus hydrochlorothiazide (HCTZ) 50 mg q.d.
Study: 10571797
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg q.d.
Study: 8927679
Drug: Low haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low haloperidol plasma level (2 ng/mL)
Study: 8927679
Drug: Moderate haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate haloperidol plasma level (10 ng/mL)
Study: 8927679
Drug: Low haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low haloperidol plasma level (2 ng/mL) followed by moderate (10 ng/mL)
Study: 8927679
Drug: Moderate haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate haloperidol plasma level (10 ng/mL) followed by low (2 ng/mL)
Study: 19321576
Drug: Multi-micronutrient-fortified biscuits
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient-fortified biscuits (including iron 6 mg, zinc 5.6 mg, iodine 35 microg, vitamin A 300 microg retinol equivalents) given 5 days/week for 4 months
Study: 10686218
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oestradiol (TE10; n = 7)
Study: 10686218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oestradiol (TE20; n = 8)
Study: 7194395
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 60 ml/kg per day
Study: 24368552
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3,000 mg × day(‐1) for 3 weeks)
Study: 3882308
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg
Study: 23458227
Drug: Fentanyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl pectin nasal spray (FPNS) 100 μg under Rhinitis condition (symptomatic without decongestant)
Study: 23458227
Drug: Fentanyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl pectin nasal spray (FPNS) 100 μg under Treated condition (symptomatic with oxymetazoline)
Study: 28286047
Drug: Acetazolamide (ACTZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACTZ) 500 mg
Study: 10102953
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg/day
Study: 9012900
Drug: Therapeutic inhalation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic inhalation of nitric oxide (NO)
Study: 24937018
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga (twice weekly)
Study: 8895944
Drug: Three-week open
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-week open oral treatment with 25 mg doxepin daily
Study: 7759676
Drug: Structured therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured therapy with treatment manuals and monitoring
Study: 11757831
Drug: Nasal mupirocin
Normalized name: mupirocin Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal mupirocin ointment
Study: 22302704
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (inoculated with NDV without treatment)
Study: 12761422
Drug: Cefadroxil prophylaxis
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil prophylaxis at 12.5-15.0 mg/kg at bedtime every alternate night (group II, n=18)
Study: 12848629
Drug: 9-month treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-month treatment
Study: 12575474
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of citalopram
Study: 28624696
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of trastuzumab and taxane chemotherapy
Study: 22115823
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine 0.4 mg
Study: 22914584
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of hepatitis B vaccine (administered to children with anti-HBs <10 mIU/mL)
Study: 22914584
Drug: Primary immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary immunization with recombinant hepatitis B vaccine
Study: 24359044
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of intravenous dexketoprofen trometamol via slow i.v. infusion (Group I)
Study: 22746387
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) monotherapy
Study: 24718568
Drug: Conventional arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional arm (no monitoring, no drug or dose changes)
Study: 17518172
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of fentanyl
Study: 21242788
Drug: Initial trophic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial trophic enteral nutrition (10 mL/hr)
Study: 16873343
Drug: Nabilone 2
Normalized name: nabilone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 2 mg
Study: 340140
Drug: Antacid plus
Normalized name: Antacid Plus
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid plus antispasmodic combination tablets (240 mg dried aluminium hydroxide, 144 mg magnesium hydroxide, 5 mg dicyclomine hydrochloride)
Study: 28296682
Drug: Anticipated death
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticipated death (withdrawal or withholding of treatment or brain death)
Study: 28026912
Drug: gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50 mg once daily
Study: 17291170
Drug: Internet-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-only treatment
Study: 9072981
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) at 30% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Study: 9072981
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) at 10% of peak maximal inspiratory pressure (PI,max) for 30 min daily, 6 days a week for 10 weeks
Study: 12888872
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH, intravenous, aPTT-adjusted for 5 to 8 days)
Study: 31594736
Drug: Maintenance intravesical
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance intravesical chemotherapy (MIC)
Study: 24570981
Drug: Implants at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants at least 10 mm long in augmented bone
Study: 21742400
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT), administered twice per week for a total of six treatments.
Study: 25764643
Drug: Intra-operative periarticular
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative periarticular injection with multimodal drugs (diclofenac, adrenaline, marcaine, morphine)
Study: 1394808
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of methotrexate (MTX), Adriamycin (ADM), and cisplatin (CDDP; IA-MAC)
Study: 6372133
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler
Study: 26963600
Drug: Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior Therapy (BT)
Study: 26836950
Drug: Quisinostat 12
Normalized name: Quisinostat
DrugBank: Quisinostat (DB12985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quisinostat 12 mg three times weekly
Study: 18758201
Drug: OxyContin tablets
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OxyContin tablets (controlled‐release oxycodone hydrochloride: 5, 10, 20, and 40 mg)
Study: 18758197
Drug: OxyContin tablets
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OxyContin tablets
Study: 22414875
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone administration
Study: 9390588
Drug: Nicardipine 2
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2 mg
Study: 27098105
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers
Study: 16919578
Drug: Myocardial oxidative
Normalized name: Ferrosoferric Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial oxidative metabolism (kmono) in NIDCM patients
Study: 16919578
Drug: Myocardial oxidative
Normalized name: Ferrosoferric Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial oxidative metabolism (kmono) in normal subjects
Study: 14586387
Drug: Air breathing
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air breathing (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Study: 23575256
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels
Study: 30778572
Drug: L-OTM
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-OTM
Study: 25820066
Drug: AVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVA vaccine
Study: 3057688
Drug: Continuous cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cyclosporine (CsA) therapy
Study: 27330977
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg risperidone
Study: 11529540
Drug: Low-dose erythromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose erythromycin (2.5 mg kg(‐1) per dose 6 hourly)
Study: 29936918
Drug: Consistently vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistently vitamin D sufficient (25(OH)D>50 nmol/l at both months 3 and 24)
Study: 27384676
Drug: DDGP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDGP regimen (cisplatin, dexamethasone, gemcitabine, pegaspargase); 6 cycles of chemotherapy
Study: 2905806
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lormetazepam
Study: 6121579
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg flunitrazepam
Study: 2228036
Drug: NOR 400
Normalized name: Nor-adrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NOR 400 mg t.i.d. for 10 days
Study: 2228036
Drug: NOR 800
Normalized name: Nor-adrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NOR 800 mg b.i.d. for 10 days
Study: 19827462
Drug: Immediate Feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Feeding (IF): CHO-PRO solution (1.2 g CHO/kg BM and 0.4 g PRO/kg BM) immediately postexercise
Study: 23537313
Drug: Weekly (W)
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W
Study: 27910037
Drug: Activated Charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated Charcoal (AC) administered at 8 hours post-dose
Study: 18945396
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment
Study: 27055527
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate monotherapy
Study: 16190795
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate (ER-MPH) 40 mg
Study: 12481675
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g) with magnesium sulphate and propantheline (15 mg)